APP and tauopathy: Studies on antidiabetic treatments often use mouse models that replicate tauopathies by overexpressing human tau mutations (P301L and P301S), linked To neurodegeneration, as well as 3xTg-AD and tau-injected APP/PS1 mice that mimic both amyloid and tau pathologies.